Activation of latent HIV using drug-loaded nanoparticles
about
Epigenetic control of HIV-1 post integration latency: implications for therapyStudies of retroviral infection in humanized miceIn vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsionsDesigned, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitroCompare analysis for the nanotoxicity effects of different amounts of endocytic iron oxide nanoparticles at single cell level.Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery.In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.In vitro reactivation of latent HIV-1 by cytostatic bis(thiosemicarbazonate) gold(III) complexesSustained-release nanoART formulation for the treatment of neuroAIDSBryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanismActivation of HIV-1 with Nanoparticle-Packaged Small-Molecule Protein Phosphatase-1-Targeting Compound.Nanotechnology and the treatment of HIV infection.Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) EnzymesTowards HIV-1 remission: potential roles for broadly neutralizing antibodies.HIV-1 transcription and latency: an update.HIV/AIDS eradicationBarriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirsHIV-1 Latency and Eradication: Past, Present and FutureExperimental Approaches for Eliminating Latent HIV.Is cure of HIV infection in sight?HDAC inhibitors in HIV.Control of HIV latency by epigenetic and non-epigenetic mechanisms.HIV reservoirs and strategies for eradication.Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.Eliminating the HIV reservoir.Attacking the HIV reservoir from the immune and viral perspective.Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.Smart nanoparticles as targeting platforms for HIV infections.The role of nanotechnology in the treatment of viral infections.HIV latency in the humanized BLT mouse.In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.Optimization and comparison of CD4-targeting lipid-polymer hybrid nanoparticles using different binding ligands.Latently infected cell activation: a way to reduce the size of the HIV reservoir?Interview: Nanomedicine and the fight against HIV/AIDS.Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.Multifunctional Nanotherapeutics for the Treatment of neuroAIDS in Drug Abusers
P2860
Q26781191-AAB72F17-5A81-4AC6-8A4A-E078C420FD4CQ26849806-D9B9DFCE-971F-4A21-AAFC-0346D11626BFQ30469832-5AED8D3F-CAD2-41F7-94D6-EE3C954C597EQ30558754-E22401D3-C98A-424A-A4B8-5096B3FA6822Q33604278-7E275914-8B45-481C-B571-2748CD38290FQ34104328-036C8A5A-2A2F-4AA6-BEE6-336682E353D9Q34469655-00A65715-6D22-4686-A0BD-D59786550CBAQ34694631-6281C8A1-4887-4898-9654-3CB48844E41AQ35082009-518A27CD-8261-483F-ADC0-1B2D4011CB8CQ35877276-E8897596-565F-40B6-8920-B42E7BE01041Q35912884-49189BD2-AD5B-42F6-BD65-7E05EDB3F62AQ35943647-B260D7EB-ACD1-43B1-90C5-20EA96A5AC7AQ36338109-CECC24BF-7237-4692-B652-D26167D017F4Q36515149-86865DC0-F522-4D36-BC3E-207AF40F1E15Q36976156-A4B86D9D-E135-43F9-8EEF-AA41F6A8E933Q37021788-1D1124BB-F7BA-452E-92C1-AA4C0FC7CE72Q37273652-8A338AAD-F0D6-41DD-8D9C-9FD832574851Q37505823-C31ED381-65A7-42A0-B54B-45390AF51FABQ37636531-AAA6EA48-76BD-4A0F-9804-813508290950Q37690804-E540AA13-329D-4D5D-AF1E-941B96C1B1A4Q37956178-B8E2CC5B-A510-4A59-882D-AD06D3FB5C26Q37972643-0E8AA597-ED55-4D37-9CA5-BF85B49B7D17Q37976293-6571F746-3E76-4B63-9845-6897869FFCBCQ37992718-2399991A-117E-4001-BF5F-02872B47A696Q37993454-3CDC386E-69F5-4915-97C9-DAFF0AEA04A6Q38067646-B27E6177-B7B8-4DE5-A7B9-DCB6CBD5AFF3Q38096822-20B1596A-E4DA-4492-8617-4BA80BFDCB1DQ38887077-2D25E2EF-2CA1-45D7-A9A7-0A97469469E7Q40106774-64D009BB-855C-4E7B-9C39-59A953CD5CC0Q40321405-5A41DBF0-41AF-4309-AC70-831F466A383DQ41932886-E72D4BA9-CDA2-4B6F-83CA-3A69981BC45AQ47225568-1C186D63-28FB-4A24-92E8-455BD8C659B3Q47311740-E61A010E-F8B7-45BA-B050-50B60DE0A515Q48375952-43B55D42-27D4-4059-B72A-8A05839E774BQ52606459-3A11A422-570F-4579-B8CE-C8F326B18888Q54978212-8556050D-2347-40A1-9186-8D342FC298A0Q56777442-A4155B7D-DD0C-4164-ACB7-494D0F93689B
P2860
Activation of latent HIV using drug-loaded nanoparticles
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Activation of latent HIV using drug-loaded nanoparticles
@ast
Activation of latent HIV using drug-loaded nanoparticles
@en
Activation of latent HIV using drug-loaded nanoparticles
@nl
type
label
Activation of latent HIV using drug-loaded nanoparticles
@ast
Activation of latent HIV using drug-loaded nanoparticles
@en
Activation of latent HIV using drug-loaded nanoparticles
@nl
prefLabel
Activation of latent HIV using drug-loaded nanoparticles
@ast
Activation of latent HIV using drug-loaded nanoparticles
@en
Activation of latent HIV using drug-loaded nanoparticles
@nl
P2093
P2860
P3181
P1433
P1476
Activation of latent HIV using drug-loaded nanoparticles
@en
P2093
Jerome A Zack
Matthew D Marsden
Michael Kovochich
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0018270
P407
P577
2011-04-05T00:00:00Z